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Targeting of the non-mutated tumor antigen
HER2/neu to mature dendritic cells induces an
integrated immune response that protects
against breast cancer in mice
Bei Wang1*, Neeha Zaidi1, Li-Zhen He2, Li Zhang1, Janelle MY Kuroiwa1, Tibor Keler2 and Ralph M Steinman1
Abstract
Introduction: Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a
protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor
receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen
uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of
this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic
cells (DCs) in a mouse breast cancer model.
Methods: We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC
(DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC
maturation stimuli (poly IC ± CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability
of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were
assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with
DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed.
Protection mechanisms and tumor-specific T cell responses were also evaluated.
Results: We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional
CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to
rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-
expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-
tumor T cell immunity was detected in tumor protected mice.
Conclusions: Immunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of
T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This
vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following
as little as 2.7 μg of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both
essential for tumor protection. This immunization strategy demonstrates great potential towards the development
of vaccines for breast cancer patients.
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Introduction
Despite recent diagnostic and therapeutic advances,
breast cancer remains the second leading cause of can-
cer mortality in females in affluent countries. Targeted
therapy for breast cancer has focused on receptor tyro-
sine kinases of the epidermal growth factor receptor
(EGFR and ErbB) family, which provide critical check-
points of cell fate decisions [1,2]. Aberrations in some
members of this gene family rank among the most fre-
quent oncogenic insults in breast cancer. The HER2/neu
proto-oncogene encodes a tyrosine kinase growth factor
receptor (p185) of the ErbB family. It is overexpressed
in about 20% to 40% of invasive breast carcinomas and
in approximately 70% of in situ ductal carcinomas.
HER2/neu overexpression usually is associated with a
poor clinical prognosis [3,4].
HER2/neu has been an attractive target for another
distinct type of targeted therapy: immune therapy.
Although HER2/neu is expressed by malignant cells as a
non-mutated self-antigen, immune tolerance is not
absolute. Both HER2/neu-specific T-cell and antibody
(Ab) responses have been detected in patients with
HER2/neu-expressing cancers [5-9]. Additionally, HER2-
specific cytolytic T-lymphocyte response has been gen-
erated in vitro with T cells from patients with HER2-
expressing tumors [6,10-12].
Given their relative simplicity of manufacture and
ability to be injected repeatedly, vaccines in a protein
format are attractive for breast and other cancers. How-
ever, soluble HER2/neu protein as a vaccine has not
been immunogenic and usually has failed to confer pro-
tection against HER2/neu-expressing tumors [13-15].
Anti-tumor immunity can be enhanced when HER2
extracellular domain is fused to cytokines or combined
with Abs fused to cytokines [15]. Other efforts to
improve immunogenicity include mannosylation of the
HER2 protein by producing the recombinant protein in
yeast [16]. On the other hand, when antigen is directly
targeted to antigen uptake receptors, efficient processing
and presentation take place. HER2/neu protein has been
incorporated into different vaccine platforms that
directly target to antigen-presenting cells (APCs).
Recently, several receptors, including B7-1/2 [17,18],
CD11c [19], CD40 [20], mannose [21], and Fcg receptors
[22], have been tested for the delivery of HER2 antigen.
Together, these studies suggest that, compared with
non-targeted vaccinations, targeting HER2 to receptors
expressed on APCs can improve HER2-specific T-cell
responses and anti-tumor immunity against HER2-
expressing tumor challenge in mouse models.
One of the dendritic cell (DC)-specific receptors that
have not been explored for HER2 vaccination is the
DEC-205 (’DEC’, CD205) receptor, a type I C-type lectin
[23]. Expression of DEC in mice is abundant on CD8a+
DCs, which have a superior capacity of cross-presenta-
tion [24,25]. Although other receptors on DCs can be
targeted [26,27], DEC is the only receptor that has been
visualized so far on the numerous DCs within the T-cell
areas of human lymphoid organs [28]. Targeting the
DEC receptor leads to efficient endocytosis of antigens
into endocytic vesicles containing major histocompat-
ibility complex (MHC) class II molecules. This results in
antigen uptake and T-cell stimulation that are hundred-
fold more efficient than fluid-phase or solute pinocytosis
[29-31]. Delivery of antigen to DEC+CD8a+ DCs in vivo
improves cross-presentation to CD8+ T cells [31,32].
Increased antigen delivery efficiency through DEC sig-
nificantly reduces the amount of protein required for
the induction of T-cell immunity. Vaccine-induced T
cells have cancer-resisting features, such as combined
CD4+ and CD8+ T-cell immunity, production of T
helper 1 (Th1)-type cytokines, and the ability to prolifer-
ate upon antigen re-challenge.
Previous studies have shown that ligation of DEC
receptor by targeting Ab conjugated to antigen does not
mature DCs but induces tolerance [30,33]. To overcome
immune tolerance mediated by steady-state DCs, DC
maturation adjuvants need to be included in the vaccine.
Examples of potent adjuvants are synthetic double-
stranded RNA, polyinosinic/polycytidylic acid (poly IC),
and its more RNase-resistant analog stabilized with
poly-L-lysine (poly ICLC). Both preclinical and clinical
studies demonstrate that poly IC and poly ICLC are
superior adjuvants for induction of potent T-cell immu-
nity. Longhi and colleagues [34] showed that, compared
with other Toll-like receptor (TLR) agonists, the TLR3
ligands poly IC and poly ICLC stand out as the most
potent adjuvants for T-cell immunity when combined
with DEC-gag monoclonal antibody (mAb) immuniza-
tion in a mouse model. A recent clinical study by Cas-
key and colleagues [35] demonstrated that poly ICLC
can be a reliable and authentic viral mimic for inducing
innate immune response and for use as a vaccine adju-
vant in humans. Poly IC is under clinical investigation
in combination with a DEC-targeted HIV protein vac-
cine in our lab (Caskey M et al unpublished results).
The aim of this study was to determine the immuno-
genicity of HER2 protein vaccine that targeted to DEC+
DCs in a preclinical mouse breast cancer model. To
deliver HER2 protein to DEC+ DCs in situ, we geneti-
cally engineered the HER2 extracellular domain into
mAbs specific for DEC and tested the immunogenicity
of this fusion mAb in mice in combination with DC
maturation stimuli. For the tumor vaccine study, we
xeno-primed mice with HER2 protein followed by a
neu-expressing tumor challenge.
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Materials and methods
Mice
Animal experiments were designed to fulfill the ethical
and scientific principles provided by the Institutional
Animal Care and Use Committee of The Rockefeller
University (New York, NY, USA) (approved protocol
08117). Mice were maintained under specific pathogen-
free conditions and were 6 to 8 weeks of age. C57BL/6,
BALB/c, FVB/N, and HLA-A2.1 transgenic mice in the
C57BL/6 background - C57BL/6-Tg(HLA-A2.1)1Enge/J
- were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). DEC-/- mice were generated and
provided by Michel Nussenzweig (The Rockefeller Uni-
versity) and are available from The Jackson Laboratory.
At least three mice per group were used in immuniza-
tion experiments.
Cell lines
The neu-expressing mammary tumor cell line NT2.5 was
derived from a spontaneous mammary tumor in female
neu-N mice (FVB/N background). The cell line was
established and kindly provided by Elizabeth M Jaffee
(Johns Hopkins University School of Medicine, Balti-
more, MD, USA). NT2.5 tumor cells were grown in a
previously defined breast media, which consisted of
RPMI (Gibco, now part of Invitrogen Corporation, Carls-
bad, CA, USA) with 20% fetal bovine serum, 1% L-gluta-
mine, 1% non-essential amino acids, 1% Na pyruvate,
0.5% penicillin/streptomycin, 0.02% gentamicin (Invitro-
gen Corporation), and 0.2% insulin (Sigma-Aldrich, St.
Louis, MO, USA). Cells were maintained at 37°C in 5%
CO2. The HER2 stably transfected tumor cell line,
E0771/E2, was generously provided by Wei-Zen Wei
(Karmanos Cancer Institute, Wayne State University,
Detroit, MI, USA). Anti-CD4 (clone GK1.5) and anti-
CD8 (clone 2.43) hybridoma cells were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and maintained in accordance with its protocols.
Construction and production of fusion monoclonal
antibody
DNA coding HER2 extracellular domain (amino acid 22-
653) was cloned in frame into the COOH terminus of
anti-DEC (DEC-HER2) or control IgG heavy chain (Ctrl
Ig-HER2) as described previously [30]. Fusion mAb was
expressed by transient transfection in 293T cells and pur-
ified on protein G columns (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA). Purified mAb was charac-
terized by SDS-PAGE and Western blot by using anti-
mouse IgG- horseradish peroxidase (IgG-HRP) (South-
ernBiotech, Birmingham, AL, USA) or anti-HER2 mAb
(clone 42; BD Transduction Laboratories, San Jose, CA,
USA). Specific binding of the fusion mAb was verified by
using Chinese hamster ovary (CHO) cells stably trans-
fected with mouse DEC receptor. Binding was detected
by flow cytometry by using phycoerythrin (PE)-conju-
gated goat anti-mouse IgG mAb (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA, USA) and
Alexa Fluor 488-conjugated mouse anti-HER2 mAb
(clone 24D2; BioLegend, San Diego, CA, USA). All Abs
had less than 0.125 endotoxin units per milligram in a
Limulus Amebocyte Lysate assay (QCL-1000; BioWhit-
taker, Walkersville, MD, USA).
Peptides
Overlapping (staggered by four amino acids) 15-mer
peptides covering the HER2 and neu extracellular
domain and HIV gag p24 protein were synthesized by
Henry Zebroski in the Proteomics Resource Center of
The Rockefeller University. The use of peptides over-
comes, in large part, the need for antigen processing by
APCs during the immune assays. The 161- and 147-
member HER2 and neu peptide libraries were divided
into seven and six pools, respectively.
Immunization
Mice were immunized intraperitoneally with 5 μg of
DEC-HER2 or Ctrl Ig-HER2 fusion mAb in combination
with 50 μg of poly IC (polyinosinic/polycytidylic acid)
(InvivoGen, San Diego, CA, USA). When indicated, a
combination of 50 μg of poly IC and 25 μg of agonistic
anti-CD40 mAb (clone 1C10) was used to mature DCs.
Intracellular cytokine staining
Bulk splenocytes were stimulated with specific peptide
pools (2 μg/mL or indicated concentration) or medium
alone in the presence of a co-stimulatory anti-CD28 mAb
(clone 37.51) for 6 hours. Brefeldin A (10 μg/mL) (Sigma-
Aldrich) was added for the last 5 hours to accumulate
intracellular cytokines. Anti-CD28 mAb was used only in
a 6-hour intracellular cytokine staining assay but not in
other T-cell immune assays, including enzyme-linked
immunosorbent assay (ELISA), enzyme-linked immuno-
sorbent spot (ELISPOT), and CFSE (5,6-carboxy fluores-
cein diacetate succinimidyl ester) dilution assays. For
functional avidity analysis, graded doses (10 to 0.0016 μg/
mL) of peptides were used to re-stimulate splenocytes.
After stimulation, cells were washed and then incubated
with anti-CD16/CD23 mAb (clone 2.4G2) to block Fcg
receptor for 15 minutes at 4°C. Cells were stained with
Live/Dead Fixable Aqua vitality dye (Invitrogen Corpora-
tion), fluorescein isothiocyanate-conjugated anti-CD4
(clone RM4-5), PerCP-Cy5.5-conjugated anti-CD8 (clone
53-6.7), and Pacific blue-conjugated anti-CD3 (clone
17A2) (eBioscience, San Diego, CA, USA) for 20 minutes
at 4°C. Cells were fixed, permeabilized (Cytofix/Cytoperm
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Plus; BD Biosciences, San Jose, CA, USA), and stained
with allophycocyanin-conjugated anti-interferon-gamma
(anti-IFNg), PE-conjugated anti-IL-2, and PECy7-conju-
gated anti-tumor necrosis factor-alpha (anti-TNF-a)
mAbs for 20 minutes at 4°C (BD Biosciences) and resus-
pended in stabilizing fixative (BD Biosciences). Data were
collected by using a BD LSR II flow cytometer (BD Bios-
ciences) and analyzed with FlowJo software (Tree Star,
Inc., Ashland, OR, USA).
CFSE dilution assay
A CFSE dilution assay was used to assess the prolifera-
tive capacity of T cells. Bulk splenocytes (2 × 107 cells/
mL) were labeled with 2.5 μM CFSE (Invitrogen Cor-
poration) in a 37°C water bath for 10 minutes. CFSE-
labeled T cells were re-stimulated with pools of peptide
(0.2 μg/mL) for 4 days, often in combination with intra-
cellular cytokine staining of cells re-stimulated for the
last 6 hours of culture.
Mouse interferon-gamma enzyme-linked immunosorbent
spot
Multi-screen-HA MAHA 54510 (Millipore, Billerica,
MA, USA) plates were coated with 10 μg/mL of purified
rat anti-mouse-IFNg mAb (clone R46A2; BD Bios-
ciences) in phosphate-buffered saline (PBS) overnight at
4°C. Plates were washed and blocked with PBS/1%
bovine serum albumin (BSA) for 1 hour at 37°C. Mag-
netic-activated cell sorting (MACS)-purified CD8+ or
CD4+ T cells (3 × 105) were cultured for 2 days with 1
× 105 purified CD11c+ spleen DCs pulsed with the pep-
tide mix (1 μg/mL) or NT2.5 tumor lysate (10 μg/mL).
Biotin-conjugated rat anti-mouse-IFNg mAb (clone
XMG 1.2, 2 μg/mL; BD Biosciences) was used as the
detection Ab. After 2-hour incubation with detection
Ab, spots were visualized with a Vectastain ABC kit
(Vector Laboratories, Inc., Burlingame, CA, USA), fol-
lowed by diaminobenzidine as the substrate (Invitrogen
Corporation). Spots were counted in an ELISPOT reader
(Autoimmun Diagnostika GmbH, Strabberg, Germany).
Mouse cytokine enzyme-linked immunosorbent assay
Splenic CD4+ and CD11c+ cells were purified by MACS.
CD4+ cells (3 × 105) were incubated with 1 × 105
CD11c+ cells with peptide mix (2 μg/mL) in 96-well U-
bottomed plates for 48 hours. Concentrations of IFNg,
IL-4, IL-10, and IL-17 in supernatant were measured by
Ready-Set-Go! ELISA sets (eBioscience).
Enzyme-linked immunosorbent assay for anti-HER2/neu
antibodies
To detect HER2-specific Ab response, we produced
FLAG-HER2 soluble protein by transient transfection of
293T cells and purification with anti-FLAG affinity gel
(Sigma-Aldrich). The quality of FLAG-HER2 protein
was verified by SDS-PAGE gel under non-reducing con-
ditions (Figure S1 of Additional file 1). We coated high-
binding ELISA plates (Nunc; Thermo Fisher Scientific
Inc., Rochester, NY, USA) with 500 ng/mL (50 ng/well)
of FLAG-HER2 overnight at 4°C. Plates were washed
with PBS/0.1% Tween-20 and blocked with PBS/0.1%
Tween 20/5% BSA for 1 hour at 37°C. Serial dilutions of
serum were added to the plates and incubated for 1
hour at 37°C. Secondary goat anti-mouse IgG-specific
Abs conjugated with HRP (SouthernBiotech) were
added and visualized with tetramethylbenzidine
(eBioscience) at room temperature for 5 to 10 minutes.
To determine the IgG isotype, anti-mouse IgG1 or
IgG2a Abs were used. The reported titers represent the
highest dilution of sample showing an OD450 (optical
density at 450 nm) of higher than 0.1. The data were
presented as the log10 Ab titer. To determine whether
serum IgG can bind to HER2/neu-expressing tumor
cells, serial diluted serum was incubated with E0771/E2
(HER2+) or NT2.5 (neu+) tumor cells for 15 minutes at
4°C. Anti-mouse IgG-PE mAbs were used to detect the
binding of serum IgG to tumor cells. Data were
acquired by using a BD LSR II flow cytometer.
Tumor protection
FVB/N mice were immunized intraperitoneally with 5
μg of DEC-HER2 or Ctrl Ig-HER2 mAb together with
50 μg of poly IC on days 0 and 28. Poly IC alone (50
μg) was injected as a negative control. Ten days after
the boost immunization, mice were inoculated subcuta-
neously with 1 × 106 NT2.5 tumor cells in the shaved
right flank. Tumor size was measured three times every
week by using a caliper. Tumor volumes were estimated
according to the formula: length × (width)2 × 0.5. For
survival analysis, tumor sizes of at least 500 mm3 were
defined as the experimental endpoint. For Ab depletion,
200 μg of CD4 or CD8 mAbs or both were given to
mice intraperitoneally after boost immunization 9, 6,
and 3 days before tumor challenge. Isotype control rat
IgG was given as a negative control. Efficiency of deple-
tion was confirmed by fluorescence-activated cell sorting
(FACS) analysis of peripheral blood cells.
Statistical analysis
All analysis was performed by using Prism 4.0 GraphPad
software (GraphPad Software, Inc., San Diego, CA,
USA). A two-sided Student t test (between two groups
or conditions) was applied to compare statistical signifi-
cance between peptide-specific responses and treatment
groups of immunized mice. Survival studies were ana-
lyzed by Kaplan-Meier survival curves and log-rank test.
Results were considered statistically significant when the
P value was less than 0.05.
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Results
HER2 extracellular domain can be introduced into a
functional DEC antibody
To deliver HER2 protein to mouse DCs directly in vivo,
we cloned the extracellular domain of HER2 (amino
acid 22-653) in frame into the heavy chain of the anti-
mouse DEC mAb (DEC-HER2) (Figure 1A). The heavy
chain of an isotype-matched non-reactive control IgG
was also engineered as a non-targeting control (Ctrl Ig-
HER2). The fusion mAbs were composed of a 140- to
approximately 150-kDa heavy chain, consistent with a
predicted mass of 90 kDa for the HER2 extracellular
domain fused to the approximately 50-kDa heavy chain
of unconjugated mouse IgG1 (Figure 1B). To verify
whether the fusion mAb bound to the mouse DEC
receptor, a stable CHO cell transfectant, expressing
mouse DEC on the surface, was stained with the indi-
cated concentration of mAb. As analyzed by FACS,
DEC-HER2 mAb, but not Ctrl Ig-HER2 mAb, demon-
strated proper DEC-binding activity (Figure 1C).
DEC targeting of HER2 induces strong and broad HER2-
specific CD4+ T cells
To determine the immunogenicity of the DEC-HER2
fusion mAb, we immunized C57BL/6 (H-2b) mice with
DEC-HER2 or Ctrl Ig-HER2 intraperitoneally at a dose
of 5 μg (equivalent to 14 pmol or 2.7 μg of HER2 pro-
tein). Poly IC (50 μg) and agonistic anti-CD40 mAb (25
μg) were used to mature DCs. In C57BL/6 mice, CD4+
T cells responded strongly to epitopes present in HER2
peptide pools 4 and 5 (Figure 2A). We also found a
weak response against HER2 epitopes in pools 3 and 7
(Figure 2A). When CD28 mAb was removed from cul-
ture, T-cell responses were reduced but remained signif-
icantly higher than background signals (Figure S2A of
Additional file 2). The T-cell response was specific to
HER2 since there was no reactivity to HIV gag peptides.
Although Ctrl Ig-HER2 vaccination induced a significant
CD4+ T-cell response against peptide pool 5, its magni-
tude was significantly weaker than that induced by
DEC-HER2 (Figure 2A). The breadth of the response
was limited to pool 5. We did not observe significant
CD4+ T-cell responses against other pools.
In addition to determining effector T-cell pool size, we
determined the proliferative capacity of vaccine-induced
CD4+ T cells upon antigen re-stimulation by CFSE dilu-
tion assays. Immunized T cells were stimulated with
HER2 or control peptides in vitro for 4 days. When
recalled with HER2 peptide pools for the last 6 hours,
the proliferating CD4+ T cells produced IFNg specifically
against HER2 (Figure 2B).
To determine whether vaccine-induced CD4+ T cells
are multi-functional (as defined by the combination of
IFNg, IL-2, and TNFa production at the single-cell level
[36]), we measured the relative proportion of potential
combinations of cytokines as depicted by pie charts and
shown in Figure S3 (left panel) of Additional file 3. The
mean percentage of CD4+ T cells producing IFNg/IL-2/
TNFa was approximately 57%. Thus, DEC-HER2 vacci-
nation elicited multi-functional CD4+ T-cell responses.
To determine the types of Th responses induced by
vaccination, we measured the production of the Th1/
Th2/Th17 cytokines (IFNg, IL-4, IL-10, and IL-17) by
ELISA. CD4+ T cells from immunized mice were co-cul-
tured with CD11c+ cells in the presence of HER2 pep-
tide pool 5 or HIV gag peptide mix for 48 hours. As
shown in Figure 2C, in mice immunized with DEC-
HER2, we detected a dominant Th1 response with little
Th2 or Th17 cytokine secretion from mice immunized
with DEC-HER2. T cells from DEC-HER2 immunized
mice produced significantly higher amounts of IFNg but
similar levels of IL-4/IL-10/IL-17 in comparison with T
cells from mice immunized with Ctrl Ig-HER2 mAb.
These data demonstrate that targeting DCs via DEC
primed strong Th1 responses against HER2.
Poly IC induces strong and broad CD4+ T-cell responses
to DEC-targeted HER2
As a monotherapy, poly IC has been tested at high doses
in patients with cancer and has been shown to have a
favorable safety profile [37-41]. To assess the adjuvant
activity of poly IC, we primed and boosted mice with
DEC-HER2 in combination with 50 μg of poly IC but
without anti-CD40 mAb. We found that poly IC as the
only adjuvant mediated significant CD4+ T-cell responses
in mice immunized with DEC-HER2 mAb but not in
mice treated with Ctrl Ig-HER2. We identified four reac-
tive HER2 peptide pools, namely pools 3, 4, 5, and 7 (Fig-
ure 3A), which are the same immunogenic pools when
poly IC and CD40 Ab were used together as the adju-
vants. The mean proportion of CD4+ T cells producing
IFNg/IL-2/TNFa was approximately 50% (right panel of
Figure S3 of Additional file 3), which is similar to the
response when poly IC and CD40 Ab were co-admini-
strated. Thus, DEC-HER2 vaccination with poly IC can
elicit multi-functional CD4+ T-cell responses.
To our knowledge, HER2-specific CD4 T-cell epitopes
have not been identified in C57BL/6 mice. To identify
the individual reactive CD4 epitopes, we re-stimulated
immune CD4+ T cells with single peptides from pools 3,
4, 5, and 7. Seven peptides were able to induce signifi-
cant IFNg production by CD4+ T cells from DEC-HER2
immunized mice (Figure S4 of Additional file 4 and
Table 1). The dominant CD4 T-cell epitopes in C57BL/
6 mice locate within the HER2284-302 region (NPEGRY
TFGASCVTACPYN).
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Figure 1 Characterization of HER2 fusion monoclonal antibody (mAb). (A) Structure of HER2 fusion mAb. C’, carboxyl-terminus; C region,
constant region; ECD, extracellular domain (amino acid 22-653); N’, amino-terminus; V region, variable region. (B) Fusion mAb (DEC-HER2 or Ctrl
Ig-HER2) was produced by transient transfection of 293T cells with the appropriate vector and purified on a protein G column. Imperial protein
staining (left panel) and Western blotting of the fusion mAb are shown, and the anti-mouse IgG1-HRP (amIgG) and anti-HER2-Biotin/SAv-HRP
(aHER2) antibodies are indicated below the figures. Lane 1: empty DEC mAb; lane 2: DEC-HER2 mAb; lane 3: Ctrl Ig-HER2 mAb. M, molecular
weight standards (in kilodaltons). (C) Fluorescence-activated cell sorting staining data show the binding capacity of graded doses (0, 0.05, 0.5,
and 5 μg/mL) of the indicated fusion mAb to the DEC or neomycin (Neo) stably transfected CHO cells. Binding was detected by fluorescence-
labeled secondary antibody specific for mouse IgG1 or HER2 antigen. CHO, Chinese hamster ovary; HER, human epidermal growth factor
receptor; Ig, immunoglobulin.
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To determine whether DEC-HER2 can induce CD4+ T-
cell responses in different MHC backgrounds, we immu-
nized BALB/c (H-2d) and FVB/N (H-2q) mice. Signifi-
cant CD4+ T-cell response was induced with DEC-
HER2 was targeted to the DEC receptor, although the
magnitude was lower than that observed in C57BL/6
mice (Figure 3B, C). The dominant epitope or epitopes
presented in BALB/c mice were located in pool 2 (Fig-
ure 3B). The amino acid sequence spanning HER2 pep-
tide pool 2 is shown in Table S1 of Additional file 5,
and the predicted I-Ad-restricted epitopes are shown in
Table S2 of Additional file 6. CD4+ T-cell responses can
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Figure 2 A single dose of DEC-HER2 fusion monoclonal antibody (mAb) vaccine immunizes HER2-specific CD4+ T cells in vivo. (A)
Groups of C57BL/6 mice were vaccinated intraperitoneally with 5 μg of DEC-HER2 or Ctrl Ig-HER2 in combination with poly IC (50 μg) and anti-
CD40 antibody (25 μg). Additional groups received adjuvants alone or were left untreated. Two weeks after immunization, splenocytes were re-
stimulated without added peptides (medium alone) or with 2 μg/mL HER2 peptide pools 1 to 7 or irrelevant HIV gag peptides. Intracellular
cytokine staining was determined by fluorescence-activated cell sorting after 6 hours of in vitro stimulation. The percentage of IFNg+CD4+ T cells
is shown as mean ± standard error with three or four mice per group. The results of one of three independent experiments are shown. (B) CFSE
dilution assay. Mice were immunized as in (A), and bulk splenocytes were labeled with 2.5 μM CFSE and re-stimulated with 0.2 μg of HER2
peptide pool 1-7 or HIV gag peptide mix or medium alone for 4 days. T-cell proliferation was analyzed in combination with intracellular cytokine
staining of the cells re-stimulated for the last 6 hours. Percentages of proliferating (CFSElow) and IFNg+CD4+ T cells are shown with three or four
mice per group. The results of one of two independent experiments are shown. (C) Th1/Th2/Th17 cytokine enzyme-linked immunosorbent assay
(ELISA). Mice were immunized as in (A). Two weeks after the boost, splenic CD4+ T cells and CD11c+ cells were isolated. CD4+ cells (3 × 105)
were incubated with 1 × 105 CD11c+ cells in 96-well U-bottomed plates in the presence of 2 μg/mL HER2 peptide pool 5 or HIV gag peptides
for 48 hours. Concentrations of IFNg/IL-4/IL-10/IL-17 in culture supernatant were measured by ELISA. The results of one of two independent
experiments (n = 4 mice per group) are shown. *P < 0.05, **P < 0.01, ***P < 0.001. CFSE, 5,6-carboxy fluorescein diacetate succinimidyl ester;
HER, human epidermal growth factor receptor; IFNg, interferon-gamma; Ig, immunoglobulin; IL, interleukin; NS, not statistically significant; poly IC,
polyinosinic/polycytidylic acid; Th, T helper.
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also be induced in the FVB/N mice, and the dominant
epitope or epitopes are located in HER2 peptide pool 4
(Table S1 of Additional file 5 and Figure 3C).
To determine whether the DEC receptor is essential
for vaccination, we immunized DEC-/- mice. DEC-HER2
did not induce HER2-specific T-cell responses in DEC-/-
mice (Figure 3D). The dependence of DEC expression
in this model is consistent with our previous studies
using other immune antigens [32,42].
To determine the pattern recognition receptor
required for poly IC, we tested TLR3-/- and TLR3-/-
MDA5-/- mice. Though significantly reduced, half of the
adjuvant effect of poly IC remained intact in TLR3-/-
mice. In contrast, poly IC completely lost its adjuvant













3x105 CD4+ cells 
Naive 
poly IC 
Ctrl Ig-HER2 + poly IC 
DEC-HER2 + poly IC 























Restimulation Medium HIV gag HER2 
Pool 5 
Wild type 
2.5 0.04 0.08 
0.10 0.03 0.04 
0.06 0.05 0.08 
0 10 2 10 3 10 4 10 50 10 
2 
10 3 10 4 
10 5 
% IFNγ+ CD4+ T cells  
E 
25 50 75 100
FVB/N 
*** 
25 50 75 100 
BALB/c 
*** 








TLR3  KO 




Figure 3 Poly IC as a mono-adjuvant for strong and broad HER2-specific CD4+ T-cell responses. C57BL/6 (A), BALB/c (B), or FVB/N (C)
mice were primed with 5 μg of DEC-HER2 + 50 μg of poly IC and boosted 4 weeks later. Two weeks after the boost, HER2-specific IFNg
production was quantified by enzyme-linked immunosorbent spot assay. All experiments were performed with at least three mice per group,
and the results of one of two or three independent experiments are shown. (D) Requirement for DEC expression. DEC-/- or wild-type C57BL/6
mice were primed and boosted 4 weeks apart with DEC-HER2 + poly IC, Ctrl Ig-HER2 + poly IC, or nothing. Two weeks after the boost,
splenocytes were harvested and re-stimulated with medium alone or 2 μg/mL HIV gag or HER2 peptide pool 5 for 6 hours. IFNg production was
measured by intracellular cytokine staining. Fluorescence-activated cell sorting blots are shown. Three or four mice were in each group, and the
results of one of two experiments are shown. (E) Requirement for pattern recognition receptors. Wild-type, TLR3 KO, or TLR3/MDA5 DKO C57BL/
6 mice were immunized with DEC-HER2 + poly IC. Two weeks after the boost vaccination, splenocytes were harvested and re-stimulated with
medium alone or 2 μg/mL HIV gag or HER2 peptide pool 5 for 6 hours. IFNg production was measured by intracellular cytokine staining. Three
mice were in each group. ***P < 0.001. HER, human epidermal growth factor receptor; IFNg, interferon-gamma; Ig, immunoglobulin; poly IC,
polyinosinic/polycytidylic acid; TLR, Toll-like receptor.
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effect in TLR3-/-MDA5-/- mice (Figure 3E). These data
suggest that both endosomal TLR3 and the cytosolic
sensor MDA5 are required for the maximal adjuvant
effect of poly IC.
Thus, targeting HER2 to DCs activated by poly IC
induced potent, broad, and multi-functional CD4+ T-cell
immunity in mice; these are important features of a suc-
cessful vaccination. Induction of T-cell immunity was
dependent on the expression of DEC receptor for anti-
gen uptake and TLR3/MDA5 for DC maturation.
HER2 protein targeted to dendritic cells can cross-prime
CD8+ T cells
To assess cross-priming of HER2 protein by DEC target-
ing, we vaccinated FVB/N (H-2q) mice with DEC-HER2
or Ctrl Ig-HER2 in combination with poly IC. We found
that HER2-specific CD8+ T-cell responses were elicited
in mice vaccinated with DEC-HER2 but not in mice
vaccinated with Ctrl Ig-HER2 mAb (Figure 4A). The
dominant epitope or epitopes are located in peptide
pool 5 (Figure 4A), and the amino acid sequence
Table 1 Identification of CD4+ T-cell responding peptides in C57BL/6 mice
Peptide pool Responding 15-mer peptide Position Sequence IFNg spots per 3 × 105 CD4+ T cells
3 p72 284-298 NPEGRYTFGASCVTA 206 ± 20.8
4 p73 288-302 RYTFGASCVTACPYN 503 ± 183.5
5 p104 405-423 EITGYLYISAWPDSL 34 ± 7.5
p105 409-427 YLYISAWPDSLPDLS 27 ± 13.6
p108 421-435 DLSVFQNLQVIRGRI 25 ± 7.5
p109 425-438 FQNLQVIRGRILHN 24 ± 7.3
7 p148 571-585 NGSVTCFGPEADQCV 43 ± 12.3
IFNg, interferon-gamma.
A B C 
2 4 6 8 
% IFNγ+ proliferating CD8+ cells 
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50 100 150
IFNγ spots/3x105 CD8+ cells 
HLA-A2 
















Ctrl Ig-HER2 + poly IC 
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*** *** *** 
Figure 4 Cross-presentation of HER2 protein by DEC-HER2 immunization. (A) FVB/N mice were primed and boosted with DEC-HER2 or Ctrl
Ig-HER2 (5 μg) in combination with poly IC (50 μg). Two weeks after the boost, spleen CD8+ T cells were purified by magnetic-activated cell
sorting and re-stimulated with spleen CD11c+ DCs in the presence of medium alone or 1 μg/mL HIV gag peptide or HER2 peptide pools. IFNg
production was measured by enzyme-linked immunosorbent spot (ELISPOT) assay. (B) Proliferative capacity of HER2-specific CD8+ T cells. Mice
were immunized as in (A), and bulk splenocytes were labeled with CFSE and re-stimulated with medium or 200 ng/mL HIV gag or HER2 peptide
pool 1-7 for 4 days. Cells were re-stimulated for the last 6 hours, and IFNg production was measured by intracellular cytokine staining. (C) HLA-
A2 transgenic mice were vaccinated as in (A), and HER2-specific CD8+ T-cell responses were measured by ELISPOT assay. Purified CD8+ T cells
were re-stimulated with medium alone or 1 μg/mL HIV gag peptide mix or HER2 peptide pool 1-7. All experiments were performed with at least
three mice per group, and the results of one of three experiments are shown. ***P < 0.001. CFSE, 5,6-carboxy fluorescein diacetate succinimidyl
ester; HER, human epidermal growth factor receptor; IFNg, interferon-gamma; Ig, immunoglobulin; poly IC, polyinosinic/polycytidylic acid.
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spanning pool 5 is shown in Table S1 of Additional file
5. We also found that HER2-specific CD8+ T cells can
proliferate and produce IFNg when re-stimulated with
HER2 peptides (200 ng/mL) (Figure 4B).
To test whether DEC targeting can enhance cross-
priming in a human HLA haplotype, we administered
DEC-HER2 + poly IC to HLA-A2 transgenic mice on the
C57BL/6 background. Although we did not detect cross-
priming in wild-type C57BL/6 mice, the HLA-A2 trans-
genic mice developed HER2-specific CD8+ T-cell
responses, as analyzed by ELISPOT assay (Figure 4C).
We identified that peptide pool 5 contained the reactive
CD8 epitope or epitopes. The amino acid sequence span-
ning HER2 pool 5 is shown in Table S1 of Additional file
5. Two previously identified HLA-A2-restricted epitopes
are located in peptide pool 5. They are HER2435-443
(ILHNGAYSL) and HER2466-474 (ALIHHNTHL) [43,44].
Thus, targeting HER2 to DCs enhanced not only Th1
responses but also cross-presentation to CD8+ T cells.
DEC-targeted HER2 vaccination xeno-primes neu-specific
CD4+ T cells
To determine whether T cells induced by human HER2
protein vaccination are able to cross-react with the
homologous rat neu protein, we re-stimulated T cells
with neu peptides. Despite amino acid sequence differ-
ences between human HER2 and rat neu, we found that
CD4+ T cells induced by DEC-HER2 vaccination were
able to secrete IFNg upon re-stimulation with the neu
peptide pool (Figure 5A). To estimate the functional
A 
Restimulation peptide pool 
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Naïve 











100 HER2 Pool 5 
EC50 = 9.55e-007 M 
neu Pool 4 
EC50 = 2.53e-006 M 
Peptide concentration (M) 
% Max Response 
Figure 5 HER2 immunization primes strong neu-specific CD4+ T-cell responses in mice. (A) C57BL/6 mice were primed with DEC-HER2 in
combination with poly IC. Two weeks after the boost, splenocytes were re-stimulated with medium alone, HIV gag peptides, HER2 peptide pool
5, or corresponding neu peptide pool 4 (2 μg/mL). IFNg production was measured by intracellular cytokine staining. (B) Functional avidity of
HER2/neu-specific CD4+ T cells. Titrated doses of HER2 or neu peptide pool were used to re-stimulate splenocytes, and IFNg production was
quantified. Data depict the percentage of maximum response at each concentration. ***P < 0.001. Results of two experiments are shown, and six
mice were in each group. EC50, concentration of peptide that leads to 50% of the maximal responses; HER, human epidermal growth factor
receptor; IFNg, interferon-gamma; poly IC, polyinosinic/polycytidylic acid.
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avidity of the vaccine-induced CD4+ T cells, we re-sti-
mulated splenocytes from mice immunized with DEC-
HER2 + poly IC with graded concentrations of HER2
peptide pool 5 or neu peptide pool 4 (from 10 to 0.0016
μg/mL or 6.67 to 0.001 μM). As shown in Figure 5B,
HER2- and neu-specific T cells have a similar EC50 (that
is, concentration of peptide that leads to 50% of the
maximal responses). Thus, xeno-priming with HER2
protein can induce homologous rat neu-specific CD4+
T-cell responses; this induction is important for tumor
vaccination studies using rat neu-expressing tumor
models.
DEC targeting leads to HER2/neu-specific humoral
immunity
To determine whether targeting HER2 to DEC can gen-
erate humoral responses, we measured serum anti-HER2
total IgG by ELISA. In FVB/N mice, both DEC-HER2
and Ctrl Ig-HER2 mAbs induced HER2-specific Ab
responses with a similar titer of at least 1,800 in total
IgG and at least 600 in IgG1 or IgG2a (Figure 6A).
To investigate whether the serum IgG can recognize
natural HER2/neu protein presented on tumor cells, we
performed flow cytometry-based assays. Serum IgG
bound to the HER2-expressing tumor cell line E0771/E2
up to a 1:400 dilution (Figure 6B). Immune sera also
bound to neu protein on the surface of NT2.5 tumor
cells at a 1:100 dilution, although the binding was much
weaker (approximately 10-fold) than binding to HER2
protein (Figure 6C). These data indicate that cross-reac-
tivity of serum HER2-specific IgG to neu protein is
weak, unlike what we observed with T-cell cross-reactiv-
ity (Figure 5). The baseline mean fluorescence index
without immune serum was similar between the two
tumor cell lines.
DEC-HER2 vaccination significantly delays tumor growth
To assess whether the vaccine-induced HER2/neu-speci-
fic T-cell immunity can mediate protective anti-tumor
immunity, we immunized FVB/N mice with DEC-HER2
or Ctrl Ig-HER2 in combination with poly IC. Ten days
after boost immunization, mice were challenged with
NT2.5 tumor cells in the mammary fat tissue. Vaccina-
tion with only 5 μg of DEC-HER2 protein with poly IC
significantly delayed tumor growth (Figure 7A).
Although Ctrl Ig-HER2 vaccination was able to induce
anti-HER2 Ab responses (Figure 6), it was unable to
protect mice from tumor outgrowth. As expected,
administration of poly IC alone did not delay tumor
growth. Although not all of the mice that received DEC-
HER2 + poly IC vaccinations were tumor-free, the survi-
val rate (up to 80 days) of DEC-HER2-immunized mice
was significantly greater than that of Ctrl Ig-HER2-trea-
ted or untreated mice.
To determine the underlying tumor protection
mechanism, we depleted CD4+, CD8+, or both popula-
tions at the effector phase, the time of tumor challenge.
Depletion efficiency was verified by FACS analysis of
peripheral blood lymphocytes the day before tumor
challenge (Figure S5 of Additional file 7). We found that
both CD4+ and CD8+ T cells were required for tumor
protection in the vaccinated mice as determined by
tumor growth kinetics (Figure 7C). Survival analysis (up
to 60 days) shows that depletion of CD4+ T cells did
not completely abrogate survival benefit of DEC-HER2
vaccination. However, depletion of CD8+ T cells com-
pletely abrogated the tumor protection effect (Figure
7D). These data suggest that CD8+ T cells play a more
critical role for long-term survival than CD4+ T cells do.
To determine the induction of anti-tumor T-cell
responses, we harvested the splenocytes 14 days after
tumor challenge and re-stimulated purified CD4+ or
CD8+ T cells with purified splenic CD11c+ cells pulsed
with peptides mix (HIV gag, HER2, or neu) or NT2.5
tumor lysate. Strong HER2 and neu-specific CD4+ (Fig-
ure 7E) and CD8+ (Figure 7F) T-cell responses against
HER2/neu were induced by DEC-HER2 but not by Ctrl
Ig-HER2. CD4+ and CD8+ T cells also produced IFNg
upon re-stimulation with NT2.5 tumor lysate-pulsed
DCs. Thus, DEC-HER2 xeno-priming significantly
increased anti-tumor immunity and this increase led to
a significant delay in tumor outgrowth. Thus, vaccine-
induced CD4+ and CD8+ T cells were both essential for
tumor protection and long-term survival.
Discussion
In this study, we found that delivery of the HER2 tumor
antigen within DEC mAb allowed efficient immuniza-
tion of HER2/neu-specific T cells at a low dose (5 μg of
chimeric Ab or 2.7 μg of HER2 protein). We also
demonstrated that vaccine-induced T-cell immunity sig-
nificantly delayed neu-expressing tumor growth in mice.
To overcome the weak T-cell immunity that is typi-
cally elicited by HER2 protein vaccines, we delivered
HER2 to the DEC+ DCs in vivo. High efficiency of tar-
geting tumor antigen to DEC+ DCs allows a significantly
lower dose of protein to achieve potent CD4+ and CD8+
T-cell responses. We found that only a single dose of 5
μg of chimeric mAb (equivalent to 2.7 μg of HER2 pro-
tein) was able to induce strong CD4+ T-cell immunity
in mice (Figure 2). On the other hand, at the same dose,
linking HER2 protein to an isotype control mAb was
inefficient in inducing T-cell immunity. Similarly, stu-
dies from other groups have shown that usually a much
higher dose of soluble HER2/neu protein is required to
induce detectable T-cell immunity [13-15,17,45]. Even at
two doses of 50 μg, soluble HER2 protein induces only
marginal T-cell immunity [14]. The robust CD4+ T-cell
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responses induced by vaccination are Th1-dominant, as
measured by high IFNg but low IL-4/IL-10/IL-17 pro-
duction (Figure 2C). Increased Th1 immunity usually is
associated with a better outcome in patients with cancer
[46,47].
The efficient induction of CD4+ T-cell responses by
our vaccine approach is dependent on the expression of
DEC receptor. In DEC-/- mice, we did not detect signifi-
cant HER2-specific T-cell immunity (Figure 3D). This
result is consistent with our previous vaccination studies
using other antigens [32,42]. The T-cell tolerance
induced by steady-state immature DCs was overcome by
administration of TLR3 agonist poly IC with the protein
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Figure 6 Induction of anti-HER2/neu humoral immunity. FVB/N mice were vaccinated with DEC-HER2 or Ctrl Ig-HER2 with poly IC as the
adjuvant. Sera were collected 2 weeks after the boost. (A) Titers of anti-HER2 IgG were quantified by enzyme-linked immunosorbent assay as
described in Materials and methods. (B, C) Binding of HER2/neu-expressing tumor cells with immune sera measured by flow cytometry. Sera
were diluted 1:100, 1:400, or 1:1,600 and incubated with HER2-expressing E0771/E2 (B) or rat neu-expressing NT2.5 (C) tumor cells for 15 minutes
at 4°C. Binding of antibody to tumor cells was detected by staining with anti-mouse IgG-PE antibody and fluorescence-activated cell sorting
analysis. Mean fluorescence indices (MFIs) are shown. **P < 0.01, ***P < 0.001. HER, human epidermal growth factor receptor; Ig,
immunoglobulin; NS, not statistically significant; PE, phycoerythrin; poly IC, polyinosinic/polycytidylic acid.
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Figure 7 Targeting HER2 protein to dendritic cells protects mice from a challenge with HER2/neu-expressing mammary tumor cells.
(A, B) FVB/N mice were immunized with DEC-HER2 or Ctrl Ig-HER2 with poly IC or poly IC alone or were left untreated. Mice were challenged
with one million NT2.5 tumor cells in the mammary fat tissue 10 days after the boost immunization. Tumor growth was monitored by caliper
measurement three times a week. Tumor volume (in cubic millimeters) is shown in (A). Survival analysis is shown in (B). Results of three
independent experiments (n = 5 per group) are shown. (C, D) To examine the mechanism of tumor protection, CD4+, CD8+, or both types of T
cells were depleted after immunization (before tumor challenge) as described in Materials and methods. Mice were challenged with one million
NT2.5 tumor cells, and tumor growth curves are shown in (C). Survival analysis is shown in (D). Results of two independent experiments (n = 10
mice per group) are shown. (E, F) Anti-tumor immunity was determined 14 days after tumor challenge. Splenic CD4+ and CD8+ cells were
Wang et al. Breast Cancer Research 2012, 14:R39
http://breast-cancer-research.com/content/14/2/R39
Page 13 of 17
by its cellular receptors TLR3 and MDA5 is essential for
the induction of HER2 immunity (Figure 3E) and this is
consistent with our previous findings [48]. We observed
a slightly increased background response to HER2 when
poly IC was combined with DEC-HER2 vaccination, but
the background response significantly decreased at later
time points (> 3 weeks) after immunization (unpub-
lished results). The observed temporary general immune
stimulation is most likely due to the bystander T-cell
activation caused by the high amounts of IFNg, IL-2,
and TNFa secreted by the vaccine-induced T cells (Fig-
ure S3 of Additional file 3). These activated bystander T
cells might in turn amplify vaccine-induced immune
response against the tumor antigen and this would
represent a beneficial outcome of our vaccine strategy.
Targeting HER2 to activated DCs enhanced not only
the magnitude but also the quality of the CD4+ T-cell
responses in four ways. First, broad T-cell responses were
developed in three MHC haplotypes (H-2d, H-2b, and H-
2q) tested here (Figure 3A and Table 1). Second, the vac-
cine-induced T cells produced multiple cytokines (IFNg,
TNFa, and IL-2), which are important in regulating the
expansion of CD4+ and CD8+ T cells (Figure S3 of Addi-
tional file 3). Third, the vaccine-induced HER2-specific
CD4+ T cells proliferated rigorously and secreted IFNg
upon antigen challenge (Figure 2B). Fourth, the HER2-
specific CD4+ T cells cross-reacted to rat neu antigen
with similar functional avidity (Figure 5), despite the
sequence differences between the two homologs.
The high quantity and quality of vaccine-induced
CD4+ T-cell responses have several implications for
tumor immunotherapy. First, they can enhance the mag-
nitude and longevity of CD8+ T-cell immunity and pro-
mote infiltration of CD8+ T cells into the tumor milieu
[49-51]. This is supported by vaccine studies reported
by Knutson and colleagues [52], who studied patients
with breast cancer. The clinical data of the authors indi-
cate that immunization with a peptide vaccine designed
to stimulate CD8+ T cells alone generates only low and
short-lived immune responses [52]. Second, HER2/neu-
specific Th1 cells can home to the tumor site, secrete
IFNg and other inflammatory cytokines in the tumor
microenvironment, and boost the function of macro-
phages and DCs [53,54]. Activation of APCs may
increase processing and presentation of endogenous
tumor antigens from dying cells, resulting in ‘epitope
spreading’, which refers to the development of immunity
to tumor antigens other than HER2/neu and which
could halt the progression of HER2/neu-negative var-
iants [55]. Third, CD4+ T cells are also cytotoxic directly
against tumor cells [56-58], although the tumor cells
that we evaluated here lack MHC II (unpublished
results).
Immunotherapy approaches that induce integrated
CD4+ and CD8+ T-cell responses are desirable. Here, we
show that DEC-HER2 induced not only strong CD4+ T-
cell responses but also significant CD8+ T-cell responses
at a low dose (Figure 4). These CD8+ T cells proliferate
rigorously upon re-stimulation with HER2 peptide in
vitro (Figure 4B). Importantly, using HLA-A2 transgenic
mice, we found that CD8+ T-cell responses can be
induced in different MHC haplotypes (Figure 4C). The
responding HER2 peptide pool 5 indeed contains two
A2-restricted HER2 epitopes that have been described
previously [43,44]. This result is consistent with previous
findings that targeting protein to activated DCs, espe-
cially CD8a+ DCs, can significantly enhance antigen
cross-presentation to CD8+ T cells [27,31,59,60].
Targeting HER2 to DEC+ DCs induced not only inte-
grated CD4+ and CD8+ T-cell responses but also serum
Ab response (Figure 6). Importantly, HER2/neu-specific
IgG induced by immunization can recognize naturally
derived HER2/neu epitopes that are expressed on
HER2/neu-expressing tumor cells (Figure 6B, C).
Although HER2-specific Ab responses between DC-tar-
geted or non-targeted HER2 protein were similar as
assessed by titer and isotypes, the breadth and func-
tional qualities of the Ab could be different.
Strong HER2-specific immunity induced by DEC-tar-
geting immunization is translated into significant anti-
tumor responses in a transplantable tumor model in
FVB/N mice. Xeno-priming mice with 5 μg of DEC-
HER2 protein in combination with poly IC significantly
delayed the development of transplantable neu-expres-
sing tumor (Figure 7). Vaccination not only delayed the
growth of the tumors (Figure 7A) but also improved the
long-term overall survival of the mice (Figure 7B).
These results indicate that an integrated CD4+ and
CD8+ T-cell immunity is the major tumor protection
mechanism in neu-expressing tumor-challenged FVB/N
mice (Figure 7C, D). These results are consistent with a
previous report [61].
purified by magnetic-activated cell sorting isolation. Splenic CD11c+ cells were purified from naïve FVB/N mice. CD4+ (E) or CD8+ (F) T cells were
re-stimulated with CD11c+ cells pulsed with 1 μg/mL of HIV gag, HER2 peptide pool 5, or neu peptide pool 4 or 10 μg/mL NT2.5 tumor lysate at
a T cell/DC ratio of 3:1 for 3 days. IFNg production was measured by enzyme-linked immunosorbent spot assay. Four mice were in each group;
the results of one of two independent experiments are shown. *P < 0.05, **P < 0.01, ***P < 0.001. HER, human epidermal growth factor receptor;
IFNg, interferon-gamma; Ig, immunoglobulin; NS, not statistically significant; PBS, phosphate-buffered saline; poly IC, polyinosinic/polycytidylic
acid.
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We found that CD8+ T cells are playing a more domi-
nant role in tumor protection as depletion of CD8+ T
cells had a more dramatic effect on tumor growth and
overall survival. Induction of HER2/neu-specific T-cell
immunity was confirmed by in vitro T-cell assays (Fig-
ure 7E, B). Interestingly, we observed a robust CD4+ T-
cell response when neu-expressing tumor-lysate-pulsed
DCs were used as the antigen source. The response is
even stronger than that using HER2/neu-peptide-pulsed
DCs as stimuli. There are three possible explanations
for this unexpected finding. First, the quantity of neu
epitopes presented on DCs may be higher with tumor-
lysate-pulsed DCs. Second, epitope spreading could be
induced with DEC-HER2 vaccination. Therefore, the
higher responses could represent a cumulative response
against HER2/neu and other tumor antigens. Third,
post-translational modifications (glycosylation and phos-
phorylation and so on) presented on naturally derived
neu epitopes, but not on synthetic peptides, may boost
T-cell recognition and enhance TCR signal strength,
resulting in a stronger CD4+ T-cell activation. In sum-
mary, our results show that targeting HER2 protein to
activated DCs in situ significantly enhances anti-tumor
T-cell immunity, and we propose that this strategy pro-
vides a feasible approach for immunotherapy in patients
with cancer.
Conclusions
We demonstrated that immunization of mice with a
HER2 protein vaccine targeting DEC+ DCs in vivo
induced high levels of T- and B-cell responses as deter-
mined by various in vitro immune assays. Non-targeted
HER2 protein was poorly immunogenic for CD4+ and
CD8+ T cells. Analysis of the quality of vaccine-induced
Th1 cells revealed multiple features that favor anti-
tumor immunity, such as breadth, proliferative capacity,
and multiple cytokine production. This vaccination
approach protected mice from neu-expressing tumor
outgrowth following as little as 2.7 μg of HER2 protein
in the vaccine. Vaccine-induced CD4+ and CD8+ T cells
were both essential for tumor protection. This vaccine
approach is feasible and cost-efficient in clinical settings.
Since a fully humanized DEC mAb has been brought
into phase I clinical trials with HIV antigens, this vac-
cine strategy would seem logical to pursue in the devel-
opment of vaccines for patients with breast cancer.
Additional material
Additional file 1: Figure S1. Characterization of FLAG-tagged HER2
recombinant protein. Extracellular domain of HER2 was cloned into
FLAG-His-tagged expression vector (pS:FLAG-His). FLAG-HER2 protein was
produced by transient transfection of 293T cells and further purified with
anti-FLAG column (Sigma). The quality of FLAG-HER2 protein was
checked with SDS-PAGE gel under non-reducing condition. 2 μg protein
was loaded in indicated well.
Additional file 2: Figure S2. Effect of agonistic CD28 mAb on
intracellular cytokine staining assay. (A) C57BL/6 mice were immunized
with DEC-HER2+poly IC. Two weeks after boost, splenocytes were
restimulated with medium alone, HIV gag peptides, or HER2 peptide
pool 1-7 with or without CD28 mAb (2 μg/mL) during the 6 h
simulation. IFNg production was measured by intracellular cytokine
staining. (B) Functional avidity of CD4+ T cells. Mice were immunized as
in (A), splenocytes were restimulated with titrated dose of HER2 peptide
pool 4 and IFNg production was measured by intracellular cytokine
staining. Data depicts the percentage of maximum response at each
concentration.
Additional file 3: Figure S3. Functional characterization of IL-2-, IFNg- or
TNFa-producing CD4+ T cells by multiparameter flow cytometry. C57BL/6
mice were immunized with DEC-HER2+poly IC. Two weeks after boost
immunization, splenocytes were restimulated with 2 μg/mL of HER2
peptide pool 5 and analyzed for cytokines production by FACS. The pie
charts show the quality of the cytokine response, comprised of seven
functionally distinct populations producing IL-2, IFNg- and TNFa,
individually or in any combination. The percentages are based on the
production of the respective cytokines within the live CD3+CD4+
population.
Additional file 4: Figure S4. Identification of HER2-specific CD4+ T cell
epitopes in C57BL/6 mice. Mice were immunized with DEC-HER2+poly
IC. Two weeks after the boost immunization, splenic CD4+ and CD11c+
cells were isolated and cocultured in the presence of 2 μg/mL indicated
individual HER2 peptide from pool 3, 4, 5, and 7. IFNg production was
quantified by ELISPOT assay. The ID of responding HER2 peptide is
indicated above the corresponding bar.
Additional file 5: Table S1. Immunogenic peptide sequences.
Additional file 6: Table S2. Prediction of I-Ad restricted HER2 epitopes.
Additional file 7: Figure S5. Depletion efficiency of CD4+ and CD8+ T
cells in peripheral blood analyzed by flow cytometry. The day before
tumor challenge, peripheral blood cells were harvested by
submandibular bleeding and depletion efficiency was analyzed by flow
cytometry. Live CD3+ cells were gated for CD4+/CD8+ population
analysis. Shown FACS dot plot from one representative mouse.
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polycytidylic acid; poly ICLC: polyinosinic:polycytidylic acid stabilized with
poly-L-lysine; Th: T helper; TLR: Toll-like receptor; TNF: tumor necrosis factor.
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